Logo
x

Search

Subscribe Now

kelun-biotech

China’s NMPA Approves Kelun-Biotech's Sacituzumab Tirumotecan (sac-TMT) for EGFR-mutant NSCLC

China’s NMPA Approves Kelun-Biotech's Sacituzumab Tirumotecan (sac-TMT) for EGFR-mutant NSCLC

  • March 11, 2025
Kelun-Biotech Entered into a Research Collaboration and Exclusive License Agreement with MSD to Develop ADC for Solid Tumors

Kelun-Biotech Entered into a Research Collaboration and Exclusive License Agreement with MSD to Develop ADC for Solid Tumors

  • July 27, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.